Health Condition 1: N049- Nephrotic syndrome with unspecified morphologic changes
Conditions
Interventions
Intervention1: Torsemide: Dose: 0.25 mg/kg/day,
Route: Oral,
Frequency: Once daily,
Duration: Till Day 7 or until weight gain is less than 5% whichever is earlier
Control Intervention1: Furosemide: D
Sponsors
All India Institute of Medical Sciences Raebareli
Eligibility
Inclusion criteria
Inclusion criteria: Children with nephrotic syndrome relapses with moderate to severe edema who will give informed consent or assent to participate in the study
Exclusion criteria
Exclusion criteria: Children less than 1 year and more than 15 years, no baseline weight records in last 3 months, presentation with hypovolemia, sepsis, shock, Known ototoxicity to Furosemide or Torsemide, Known hypersensitivity to Furosemide or Torsemide, severe hyponatremia at admission, Anuria in last 12 hours of admission, Not willing to give informed consent or assent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To compare the efficacy of Torsemide versus Furosemide for edema control in children with euvolemic or hypervolemic NS relapses Timepoint: 18 months from the first enrolment | — |
Secondary
| Measure | Time frame |
|---|---|
| (a) To compare side effect profile and complications of Torsemide versus Furosemide. (b) To establish the safety of torsemide in Indian children with nephrotic syndrome relapses. Timepoint: 18 months from the first enrolment | — |
Countries
India
Contacts
Public ContactDr. Mritunjay Kumar
All India Institute of Medical Sciences Raebareli
Outcome results
None listed